• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

    6/5/25 1:58:00 PM ET
    $AMGN
    $DIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Get the next $AMGN alert in real time by email

    TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

    The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Disney's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?studyid=16958122.

    A full report on Disney will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc.  (AMGN: NASDAQ), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-the-walt-disney-co-nyse-dis-302474596.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $DIS

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    3/10/2026$350.00Hold
    Jefferies
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    Walt Disney Company
    $DIS
    2/3/2026$135.00Overweight
    Morgan Stanley
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    Amgen Inc.
    $AMGN
    1/7/2026$380.00Buy
    UBS
    Amgen Inc.
    $AMGN
    12/5/2025Hold → Buy
    Erste Group
    Amgen Inc.
    $AMGN
    11/24/2025$318.00Hold
    Truist
    Amgen Inc.
    $AMGN
    11/13/2025$385.00Sector Outperform
    Scotiabank
    More analyst ratings

    $AMGN
    $DIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chang Amy bought $98,791 worth of Disney Common Stock (916 units at $107.85), increasing direct ownership by 7% to 14,720 units (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    2/17/26 6:07:20 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Gorman James P bought $2,013,943 worth of Disney Common Stock (18,000 units at $111.89) (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    12/15/25 4:52:58 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Mcdonald Calvin bought $999,994 worth of Disney Common Stock (11,756 units at $85.06), increasing direct ownership by 111% to 22,313 units (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    8/9/24 4:33:36 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Walt Disney Company

    DEFA14A - Walt Disney Co (0001744489) (Filer)

    3/5/26 5:21:06 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 8-K filed by Walt Disney Company

    8-K - Walt Disney Co (0001744489) (Filer)

    3/3/26 4:31:22 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Walt Disney Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Walt Disney Co (0001744489) (Filer)

    2/24/26 4:31:47 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Walt Disney Company to Webcast Its Annual Meeting of Shareholders

    The annual meeting of shareholders of The Walt Disney Company (NYSE:DIS), including remarks by management regarding the Company, will be available live via webcast at www.disney.com/investors beginning at 1:00 p.m. ET/ 10:00 a.m. PT on March 18, 2026. The webcast presentation will be archived. Webcast may include forward-looking information. View source version on businesswire.com: https://www.businesswire.com/news/home/20260311207476/en/ Carlos Gomez Investor Relations (818) 560-1933 David Jefferson Corporate Communications (818) 560-4832

    3/11/26 1:00:00 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

    THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jasper van Grunsven, senior vice president of rare disease at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferenc

    3/5/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

    THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge

    3/4/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $DIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AMGN
    $DIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AMGN
    $DIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Amgen with a new price target

    Jefferies initiated coverage of Amgen with a rating of Hold and set a new price target of $350.00

    3/10/26 8:40:05 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Walt Disney with a new price target

    Morgan Stanley resumed coverage of Walt Disney with a rating of Overweight and set a new price target of $135.00

    2/3/26 6:56:53 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Chairman, CEO and President Bradway Robert A covered exercise/tax liability with 84,285 shares and exercised 119,782 shares at a strike of $156.35, increasing direct ownership by 8% to 492,643 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/6/26 7:32:13 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Operations Santos Esteban was granted 11,259 shares, increasing direct ownership by 15% to 87,877 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/5/26 8:43:34 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP & Chief Technology Officer Reese David M was granted 12,063 shares, increasing direct ownership by 34% to 47,650 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/5/26 8:42:19 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $DIS
    Leadership Updates

    Live Leadership Updates

    View All

    Josh D'Amaro Named Next Chief Executive Officer of The Walt Disney Company

    Dana Walden To Become President and Chief Creative Officer of The Walt Disney Company The Walt Disney Company (NYSE:DIS) Board of Directors announced today that, in a unanimous vote held on Monday, it elected Disney Experiences Chairman Josh D'Amaro to become Chief Executive Officer of The Walt Disney Company, effective at the upcoming Annual Meeting on March 18, 2026, when he will succeed longtime Disney CEO Robert A. Iger. The Board also intends to appoint D'Amaro as a director immediately following that meeting. As head of the company's largest business segment with $36 billion in annual revenue in FY2025 and 185,000 Cast Members and employees worldwide, D'Amaro, a 28-year Disney veter

    2/3/26 8:30:00 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Benjamin Swinburne to Join Disney as Executive Vice President of Investor Relations and Corporate Strategy

    Benjamin Swinburne has been named Executive Vice President of Investor Relations and Corporate Strategy for The Walt Disney Company (NYSE:DIS), it was announced today by Hugh F. Johnston, Senior Executive Vice President and Chief Financial Officer. Swinburne will join Disney in the near future and report directly to Johnston. He has most recently served as Managing Director and Head of US Media and Telecom & Cable Services Research at Morgan Stanley. "Ben has been one of the industry's most respected media analysts and brings deep insight into the evolving global entertainment landscape," said Johnston. "His analytical rigor, strategic perspective, and long-standing knowledge of our busin

    1/30/26 9:00:00 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Disney and Formula 1® Collaboration to Launch at Las Vegas Grand Prix with Spectacular Show at the Fountains of Bellagio

    Disney and Formula 1's "Fuel the Magic" Campaign will Deliver Unforgettable Fan Experiences, Exclusive Content and Elevated Products  Link to Media Assets Here Link to Social Content Here GLENDALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Disney and Formula 1® announced today their highly anticipated collaboration will kick off at the Las Vegas Grand Prix this November. As revealed in May, this exciting global relationship will "fuel the magic" for fans by blending world-class sports with Disney's iconic storytelling and an exclusive Formula 1 merchandise line.  A Spectacular Kic

    10/28/25 6:00:00 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    Financials

    Live finance-specific insights

    View All

    AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

    THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.About AmgenAmgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge

    3/4/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

    THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the fourth quarter, total revenues increased 9% to $9.9 billion in comparison to the fourth quarter of 2024.Product sales grew 7%, driven by 10% volume gro

    2/3/26 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Walt Disney Company Reports First Quarter Earnings for Fiscal 2026

    The Walt Disney Company (NYSE:DIS) today reported earnings for its first quarter ended December 27, 2025. Financial Results for the Quarter: Revenues increased 5% for the quarter to $26.0 billion from $24.7 billion in Q1 fiscal 2025. Income before income taxes for Q1 of $3.7 billion was comparable to Q1 fiscal 2025. Total segment operating income(1) decreased 9% for the quarter to $4.6 billion from $5.1 billion in Q1 fiscal 2025. Diluted earnings per share (EPS) for Q1 decreased to $1.34 from $1.40 in Q1 fiscal 2025. Adjusted EPS(1) for Q1 decreased to $1.63 from $1.76 in Q1 fiscal 2025. Key Points: Entertainment: Revenue increased 7% compared to Q1 fiscal 2025. Operatin

    2/2/26 6:40:00 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Walt Disney Company (Amendment)

    SC 13G/A - Walt Disney Co (0001744489) (Subject)

    2/13/24 4:55:53 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    1/30/24 11:35:57 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care